On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
"I think all disciplines go through a process, a journey of being imagined and then becoming a science and then becoming a discipline of...
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I...
"It's really a very important challenge we had from the very beginning, to see how to stabilize nanoparticles with the messenger RNA so they...